1. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Issue 15 (November 2015) Authors: Symonds, R Paul; Gourley, Charlie; Davidson, Susan; Carty, Karen; McCartney, Elaine; Rai, Debbie; Banerjee, Susana; Jackson, David; Lord, Rosemary; McCormack, Mary; Hudson, Emma; Reed, Nicholas; Flubacher, Maxine; Jankowska, Petra; Powell, Melanie; Dive, Caroline; West, Catharine M L; Paul, James Journal: Lancet oncology Issue: Volume 16:Issue 15(2015) Page Start: 1515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dynamics of circulating vascular endothelial growth factor‐A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. Issue 8 (13th April 2019) Authors: Zhou, Cong; Taylor, Sarah; Tugwood, Jonathan; Simpson, Kathryn; Jayson, Gordon C.; Symonds, Paul; Paul, James; Davidson, Susan; Carty, Karen; McCartney, Elaine; Rai, Debbie; Dive, Caroline; West, Catharine Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 8(2019) Page Start: 1781 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗